Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation

Roy Khalife, Lindsay Cowley, Alan T. Tinmouth, Lisa D. Duffett, Vanessa Bourck, Alfonso Iorio, Davide Matino, Kay Decker, Karen Strike, David Page, Natasha Pardy, Jerome M. Teitel, Haowei Linda Sun

Blood (2024) 144 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2024-198579

Published: 2024

Journal Articles

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Blood (2024) 144 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2024-208486

Published: 2024

Journal Articles

Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme TM

Lynn Malec, Davide Matino, Kieran Wynne-Cattanach, Chris Blazos, Duygu Bozkaya, Anne-Laure Tardy, Sylvie Bozzi, Jennifer Dumont

Blood (2024) 144 (Supplement 1): 3973.

https://doi.org/10.1182/blood-2024-193803

Published: 2024

Journal Articles

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Laurent Frenzel, Kaan Kavakli, Andrew D. Leavitt, Ali Bülent Antmen, Davide Matino, Margareth Ozelo, Hazza Alzahrani, Barbara A. Konkle, Maria de los Angeles Resa, Annie F. Fang, Jasmine Healy, Delphine Agathon, Francesca Biondo, Frank Plonski

Blood (2024) 144 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2024-193368

Published: 2024

Journal Articles

Investigating the Impact of FIX Fc Fusion on Its Extravascular Distribution and Hemostatic Properties

Bonnie Chu, Michela Ronconi, Hasam Madarati, Colin Kretz, Peter L. Gross, Anthony K C Chan, Davide Matino

Blood (2024) 144 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2024-193406

Published: 2024

Journal Articles

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Robert Klamroth, Stephanie P'ng, Sophie Susen, Davide Matino, Pratima Chowdary, Angela C Weyand, Toshko Lissitchkov, Young-Shil Park, María Teresa Alvarez-Román, Liqi Feng, Helena Palmborg, Jennifer Dumont, Elena Santagostino, Lara Mamikonian, Keiji Nogami

Blood (2024) 144 (Supplement 1): 717.

https://doi.org/10.1182/blood-2024-204533

Published: 2024

Journal Articles

Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment

Davide Matino, Travis Gould, John Teeter, Carrie Turich Taylor, Regina McDonald, Andrew Palladino

Blood (2024) 144 (Supplement 1): 716.

https://doi.org/10.1182/blood-2024-205975

Published: 2024

Journal Articles

Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety

Suchitra Acharya, Davide Matino, Johnny Mahlangu, Carrie Turich Taylor, Eunhee Hwang, Tina Hinnershitz, Eugeny Mefyod, Andrew Palladino, Francesca Biondo, Travis Gould, John Teeter

Blood (2023) 142 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2023-174682

Published: 2023

Journal Articles

Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial

Davide Matino, Suchitra Acharya, Andrew Palladino, Eunhee Hwang, Regina McDonald, Carrie Turich Taylor, John Teeter

Blood (2023) 142 (Supplement 1): 285.

https://doi.org/10.1182/blood-2023-181263

Published: 2023

Journal Articles

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Letizia Polito, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2023) 142 (Supplement 1): 1240.

https://doi.org/10.1182/blood-2023-174057

Published: 2023

Journal Articles

Effects of Prolonged Tourniquet Application on Coagulation and Fibrinolysis in Rats

Jason Chung, Owais Mian, Ivan Stevic, Sajjad Afraz, Anthony KC Chan, Howard H.W. Chan, Bret M Evers, Davide Matino

Blood (2023) 142 (Supplement 1): 5411.

https://doi.org/10.1182/blood-2023-190347

Published: 2023

Journal Articles

Hemostatic Profile at Diagnosis in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of Cases from the Literature

Paul Thuan Tieu, Nandhitha Ragunayakam, Davide Matino, Anthony Chan

Blood (2022) 140 (Supplement 1): 11581–11582.

https://doi.org/10.1182/blood-2022-169794

Published: 2022

Journal Articles

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2022) 140 (Supplement 1): 8465–8467.

https://doi.org/10.1182/blood-2022-157531

Published: 2022

Journal Articles

Von Willebrand Factor Expression in Endothelium in a Co-Culturing System of Acute Lymphoblastic Leukemia

Paul T. M. Tieu, Ivan Stevic, Davide Matino, Anthony K.C. Chan

Blood (2021) 138 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2021-154405

Published: 2021

Journal Articles

Comparing Exercise-Induced Musculoskeletal Bleeding in Murine Models of Hemophilia A and B

Paul T. M. Tieu, Anthony K.C. Chan, Peter L. Gross, Davide Matino

Blood (2021) 138 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2021-154364

Published: 2021

Journal Articles

Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study

Omotola O. Olasupo, Charles Nakar, Alfonso Iorio, Craig Haddix, Thushara Mathew, Lynn M Malec, Davide Matino, Lawrence Mbuagbaw, Jean-Eric Tarride, Amy D. Shapiro

Blood (2021) 138 (Supplement 1): 4990.

https://doi.org/10.1182/blood-2021-147550

Published: 2021

Journal Articles

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Fabian Sanabria, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2021) 138 (Supplement 1): 347.

https://doi.org/10.1182/blood-2021-147195

Published: 2021

Journal Articles

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Adrienne Lee, MD, Federico Germini, MD MSc, Man-Chiu Poon, MD, Arun Keepanasseril, Quazi Ibrahim, MSc, Aijing Shang, MD PhD, Francis Nissen, Oliver Meier, Cami S. Sima, MD, Davide Matino, Alfonso Iorio, MDPhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137320

Published: 2020

Journal Articles

Anti-FVIII Antibody and Inhibitor Development Patterns in Hemophilia A Mouse Models: A Systematic Review

Sajjad Afraz, MD MSc, George Zhao, Davide Matino, MD MSc, Anthony K.C. Chan, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 2402.

https://doi.org/10.1182/blood-2019-131441

Published: 2019

Journal Articles

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers

Lynn M Malec, MD, Stacy E. Croteau, Michael Callaghan, MD, Davide Matino, MD MSc, Kenneth Dale Friedman, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 2407.

https://doi.org/10.1182/blood-2019-126196

Published: 2019

NARROW

From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific Programme TM

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Investigating the Impact of FIX Fc Fusion on Its Extravascular Distribution and Hemostatic Properties

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment

Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety

Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Effects of Prolonged Tourniquet Application on Coagulation and Fibrinolysis in Rats

Hemostatic Profile at Diagnosis in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of Cases from the Literature

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Von Willebrand Factor Expression in Endothelium in a Co-Culturing System of Acute Lymphoblastic Leukemia

Comparing Exercise-Induced Musculoskeletal Bleeding in Murine Models of Hemophilia A and B

Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Anti-FVIII Antibody and Inhibitor Development Patterns in Hemophilia A Mouse Models: A Systematic Review

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only